Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 1/2016

17.12.2015

High residual platelet reactivity (HRPR) for adenosine diphosphate (ADP) stimuli is a determinant factor for long-term outcomes in acute ischemic stroke with anti-platelet agents: The meaning of HRPR after ADP might be more prominent in large atherosclerotic infarction than other subtypes of AIS

verfasst von: Jae-Kwan Cha, Hyun-Seok Park, Hyun-Wook Nah, Dae-Hyun Kim, Myong-Jin Kang, Jae-Hyung Choi, Jae-Taeck Huh, Hyun-Kyung Suh

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

High residual platelet activation (HRPA) after ADP stimuli has associated with recurrent vascular events in acute atherothrombosis with the use of antiplatelet agents (APAs). However, there has been little evidence supporting this association in acute ischemic stroke (AIS). In this study, we evaluated the influences of HRPR after ADP stimuli on the 1-year incidence of recurrent cardiovascular events and mortality in AIS with APAs. We conducted an observational, referral center cohort study on 968 AIS patients with APAs from January 2010 to December 2013 who were evaluated using optical platelet aggregometry (OPA). All patients received the dual APA combination of aspirin and clopidogrel or aspirin alone. We evaluated their platelet function 5 days after hospital admission using OPA. HRPR after ADP stimuli was defined as platelet aggregation of 70 % or greater according to OPA after 10 µM ADP stimuli. The primary endpoint was a composite of all causes of death, myocardial infarction, and stroke at the 1-year follow-up. The secondary endpoints were each component of the primary endpoint. The event rate of primary endpoint was 11.3 % (109/968). Its rate was significantly higher in the patients with HRPR (16.7 %) than in those without (9.7 %). HPRP was independently associated with the primary endpoint (OR = 1.97, CI 1.22–3.18, p < 0.01). According to the AIS subtype, the presence of HRPR was independently significant for the occurrence of the primary endpoint in the large artery atherosclerosis (LAA) subtype only (OR = 2.26, CI 1.15–4.45, p = 0.02). In this study, the presence of HRPR after ADP stimuli is associated with a poor long-term outcome after acute ischemic stroke. In particular, the influence of this factor might be more prominent in LAA compared with other types of AIS.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Amsterdam EA, Wenger NK, Brindis RG et al (2014) 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 23:2354–2394CrossRef Amsterdam EA, Wenger NK, Brindis RG et al (2014) 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 23:2354–2394CrossRef
2.
Zurück zum Zitat Jauch EC, Saver JL, Adams HP Jr et al (2013) American Heart Association Stroke Council: Council on Cardiovascular Nursing: Council on Peripheral Vascular Disease: Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44:870–947 Jauch EC, Saver JL, Adams HP Jr et al (2013) American Heart Association Stroke Council: Council on Cardiovascular Nursing: Council on Peripheral Vascular Disease: Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44:870–947
3.
Zurück zum Zitat Parodi G, Marcucci R, Valenti R et al (2011) High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 306:1215–1223CrossRefPubMed Parodi G, Marcucci R, Valenti R et al (2011) High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 306:1215–1223CrossRefPubMed
4.
Zurück zum Zitat Valenti R, Marcucci R, Capodanno D et al (2015) Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study. J Thromb Thrombolysis 40:76–82CrossRefPubMed Valenti R, Marcucci R, Capodanno D et al (2015) Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study. J Thromb Thrombolysis 40:76–82CrossRefPubMed
5.
Zurück zum Zitat Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502CrossRefPubMed Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502CrossRefPubMed
6.
Zurück zum Zitat Teal PA (2004) Recent clinical trial results with antiplatelet therapy: implications in stroke prevention. Cerebrovasc Dis 17(Suppl 3):6–10CrossRefPubMed Teal PA (2004) Recent clinical trial results with antiplatelet therapy: implications in stroke prevention. Cerebrovasc Dis 17(Suppl 3):6–10CrossRefPubMed
7.
Zurück zum Zitat CAST (Chinese Acute Stroke Trial) Collaborative Group (1997) Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349:1641–1649CrossRef CAST (Chinese Acute Stroke Trial) Collaborative Group (1997) Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349:1641–1649CrossRef
8.
Zurück zum Zitat The International Stroke Trial (IST) (1997) A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 349:1569–1581CrossRef The International Stroke Trial (IST) (1997) A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 349:1569–1581CrossRef
9.
Zurück zum Zitat Wang Y, Wang Y, Zhao X et al (2013) Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 369:11–19CrossRefPubMed Wang Y, Wang Y, Zhao X et al (2013) Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 369:11–19CrossRefPubMed
10.
Zurück zum Zitat Wong KS, Chen C, Fu J et al (2010) Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 9:489–497CrossRefPubMed Wong KS, Chen C, Fu J et al (2010) Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 9:489–497CrossRefPubMed
11.
Zurück zum Zitat Zhang Q, Wang C, Zheng M et al (2015) Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. Cerebrovasc Dis 39:13–22PubMed Zhang Q, Wang C, Zheng M et al (2015) Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. Cerebrovasc Dis 39:13–22PubMed
12.
Zurück zum Zitat Yi X, Lin J, Wang C, Zhang B et al (2007) A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke. J Stroke Cerebrovasc Dis 23:1975–1981CrossRef Yi X, Lin J, Wang C, Zhang B et al (2007) A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke. J Stroke Cerebrovasc Dis 23:1975–1981CrossRef
13.
Zurück zum Zitat Gurbel PA, Bliden KP, DiChiara J et al (2007) Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115:3156–3164CrossRefPubMed Gurbel PA, Bliden KP, DiChiara J et al (2007) Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115:3156–3164CrossRefPubMed
14.
Zurück zum Zitat Pulcinelli FM, Pignatelli P, Celestini A et al (2004) Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 43:979–998CrossRefPubMed Pulcinelli FM, Pignatelli P, Celestini A et al (2004) Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 43:979–998CrossRefPubMed
15.
Zurück zum Zitat Kim BJ, Han MK, Park TH et al (2014) Current status of acute stroke management in Korea: a report on a multicenter, comprehensive acute stroke registry. Int J Stroke 9:514–518CrossRefPubMed Kim BJ, Han MK, Park TH et al (2014) Current status of acute stroke management in Korea: a report on a multicenter, comprehensive acute stroke registry. Int J Stroke 9:514–518CrossRefPubMed
16.
Zurück zum Zitat Ko Y, Lee S, Chung JW et al (2014) MRI-based algorithm for acute ischemic stroke subtype classification. J Stroke 3:161–172CrossRef Ko Y, Lee S, Chung JW et al (2014) MRI-based algorithm for acute ischemic stroke subtype classification. J Stroke 3:161–172CrossRef
17.
Zurück zum Zitat Gum PA, Kottke-Marchant K, Welsh PA et al (2003) A prospective, blinde determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961–965CrossRefPubMed Gum PA, Kottke-Marchant K, Welsh PA et al (2003) A prospective, blinde determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961–965CrossRefPubMed
18.
Zurück zum Zitat Cha JK, Jeon HW, Kang MJ (2008) ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. Eur J Neurol 15:1304–1308CrossRefPubMed Cha JK, Jeon HW, Kang MJ (2008) ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. Eur J Neurol 15:1304–1308CrossRefPubMed
19.
Zurück zum Zitat Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EL (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961–965CrossRefPubMed Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EL (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961–965CrossRefPubMed
20.
Zurück zum Zitat Buonamici P, Marucci R, Migliorini A et al (2007) Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49:2312–2317CrossRefPubMed Buonamici P, Marucci R, Migliorini A et al (2007) Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49:2312–2317CrossRefPubMed
21.
Zurück zum Zitat Migliorini A, Valenti R, Marucucci R et al (2009) High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation 120:2214–2221CrossRefPubMed Migliorini A, Valenti R, Marucucci R et al (2009) High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation 120:2214–2221CrossRefPubMed
22.
Zurück zum Zitat Mattiasson I, Letiiagen S, Hillarp A (2003) Increased to ADP aggression in aspirin treated patients with recurrent ischemic stroke? Int Angio 22:239–242 Mattiasson I, Letiiagen S, Hillarp A (2003) Increased to ADP aggression in aspirin treated patients with recurrent ischemic stroke? Int Angio 22:239–242
23.
Zurück zum Zitat Marquardt L, Ruf A, Mansmann U, Winter R, Shuler M, Buggle F, Meyer H, Grau AJ (2002) Course of platelet activation markers after ischemic stroke. Stroke 33:2570–2574CrossRefPubMed Marquardt L, Ruf A, Mansmann U, Winter R, Shuler M, Buggle F, Meyer H, Grau AJ (2002) Course of platelet activation markers after ischemic stroke. Stroke 33:2570–2574CrossRefPubMed
24.
Zurück zum Zitat Marquardt L, Anders C, Buggle F et al (2009) Leukocyte-platelet aggregates in acute and subacute ischemic stroke. Cerebrovasc Dis 38:276–282CrossRef Marquardt L, Anders C, Buggle F et al (2009) Leukocyte-platelet aggregates in acute and subacute ischemic stroke. Cerebrovasc Dis 38:276–282CrossRef
25.
Zurück zum Zitat Cha JK, Jeong MH, Jang JY et al (2003) Serial measurement of surface expressions of CD63, P-selectin and CD40 ligand on platelets in atherosclerotic ischemic stroke. A possible role of CD40 ligand on platelets in atherosclerotic ischemic stroke. Cerebrovasc Dis 16:376–382CrossRefPubMed Cha JK, Jeong MH, Jang JY et al (2003) Serial measurement of surface expressions of CD63, P-selectin and CD40 ligand on platelets in atherosclerotic ischemic stroke. A possible role of CD40 ligand on platelets in atherosclerotic ischemic stroke. Cerebrovasc Dis 16:376–382CrossRefPubMed
27.
Zurück zum Zitat Seet RC, Friedman PA, Rabinstein AA (2011) Prolonged rhythm monitoring for the detection of occult paroxysmal atrial fibrillation in ischemic stroke of unknown cause. Circulation 124:477–486CrossRefPubMed Seet RC, Friedman PA, Rabinstein AA (2011) Prolonged rhythm monitoring for the detection of occult paroxysmal atrial fibrillation in ischemic stroke of unknown cause. Circulation 124:477–486CrossRefPubMed
28.
Zurück zum Zitat Flint AC, Banki NM, Ren X et al (2012) Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the Stroke and Monitoring for PAF in Real Time (SMART) Registry. Stroke 43:2788–2790CrossRefPubMed Flint AC, Banki NM, Ren X et al (2012) Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the Stroke and Monitoring for PAF in Real Time (SMART) Registry. Stroke 43:2788–2790CrossRefPubMed
29.
Zurück zum Zitat Gurbel PA, Becker RC, Mann KG et al (2007) Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50:1822–1834CrossRefPubMed Gurbel PA, Becker RC, Mann KG et al (2007) Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50:1822–1834CrossRefPubMed
30.
Zurück zum Zitat Bennett D, Yan B (2013) Suboptimal response to clopidogrel: a genetic risk factor for recurrent ischaemic stroke. J Clin Neurosci 20:767–770CrossRefPubMed Bennett D, Yan B (2013) Suboptimal response to clopidogrel: a genetic risk factor for recurrent ischaemic stroke. J Clin Neurosci 20:767–770CrossRefPubMed
Metadaten
Titel
High residual platelet reactivity (HRPR) for adenosine diphosphate (ADP) stimuli is a determinant factor for long-term outcomes in acute ischemic stroke with anti-platelet agents: The meaning of HRPR after ADP might be more prominent in large atherosclerotic infarction than other subtypes of AIS
verfasst von
Jae-Kwan Cha
Hyun-Seok Park
Hyun-Wook Nah
Dae-Hyun Kim
Myong-Jin Kang
Jae-Hyung Choi
Jae-Taeck Huh
Hyun-Kyung Suh
Publikationsdatum
17.12.2015
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 1/2016
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-015-1304-5

Weitere Artikel der Ausgabe 1/2016

Journal of Thrombosis and Thrombolysis 1/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.